Boehringer Ingelheim Animal Health introduces Ingelvac® MycoMAX in Canada — the first and only commercially available swine vaccine for Mycoplasma hyorhinis

Ingelvac® MycoMAX is licensed for use in pigs three weeks of age or older, can help prevent problems associated with Mycoplasma hyorhinis and reduce antibiotic usage.

Burlington, Canada, March 1, 2019 – Until now, there have been no commercially available vaccines with demonstrated efficacy against Mycoplasma hyorhinis (Mhr). Boehringer Ingelheim Animal Health has introduced Ingelvac® MycoMAX filling an unmet need in the swine industry for proven protection associated with Mhr¹.

Developed and sold by Boehringer Ingelheim Animal Health, Ingelvac® MycoMAX is the first Mhr vaccine for pigs with demonstrated efficacy and safety. It offers:

• Proven to protect against arthritis, pericarditis, lameness, and peritonitis associated with Mhr¹
• Effectively protects pigs in the nursery phase, when they are most susceptible to Mhr infection resulting in clinical disease^2-6
• Pig’s average daily gain three weeks following challenge demonstrated a highly significant statistical increase in post-challenge weight gain (P < .0001)⁷ of 0.42 kg/day vs Controls at 0.26 kg/day
• Facilitates a control program that supports good antibiotic stewardship practices

“The traditional control of this pathogen, considered endemic in swine herds worldwide, is based on antimicrobial therapy and this, combined with economic losses from mortality and reduced performance due to lesions in various tissues, can have a negative impact both on the return on investment and animal welfare,” said Dr. Cesar Caballero, MVZ, DVM, DVSc, EVP., Technical Services Veterinarian for Boehringer Ingelheim Animal Health Swine Division in Canada.

We bring innovative animal healthcare solutions to veterinarians and producers across Canada. Boehringer Ingelheim Animal Health is guided by a passionate belief in which no animal suffers from a preventable disease. We are committed to providing advanced, preventative animal healthcare and developing vaccines, parasiticides and pharmaceuticals that protect animals against disease and pain.

Boehringer Ingelheim (Canada) Ltd.

Improving the health and quality of life of patients is the goal of Boehringer Ingelheim, a research-driven pharmaceutical company. In doing so, the focus is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. Research and development expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs approximately 600 people across Canada.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.ca or in our annual report: http://annualreport.boehringer-ingelheim.com. 

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of 3.9 billion euros and around 10,000 employees worldwide, we are present in more than 150 markets. For more information click here.

References:

1. BIVI studies 2014245, 2015095, 2016077 published on http://productdata.aphis.usda.gov.
2. Martinson B, Minion FC, Jordan D. Development and optimization of a cell-associated challenge model for Mycoplasma hyorhinis in 7-week-old caesarean-derived, colostrum-deprived pigs. Can J Vet Res. 2018;82:12–23.
3. Clavijo MJ, Murray D, Oliveira S, Rovira A. Infection dynamics of Mycoplasma hyorhinis in three commercial pig populations. Vet Rec. 2017;181(3):68. doi:10.1136/vr.104064.
4. Straw BE, Zimmermann JJ, D’Allaire S, Taylor DJ. Diseases of Swine. 9th ed. Ames, IA: Blackwell Publishing; 2006.
5. Morita T, Ohiwa S, Shimada A, Kazama S, Yagihashi T, Umemura T. Intranasally inoculated Mycoplasma hyorhinis causes eustachitis in pigs. Vet Pathol. 1999;36:174–178.
6. Lin JH, Chen SP, Yeh KS, Weng CN. Mycoplasma hyorhinis in Taiwan: diagnosis and isolation of swine pneumonia pathogen. Vet Microbiol. 2006;115:111–116.
7. Martinson B, Zoghby W, Barrett K, Bryson L, Christmas R, Minion FC, Kroll J. Efficacy of an inactivated Mycoplasma hyorhinis vaccine in pigs. Vaccine. 2018;36:408–412.

Ingelvac® is a registered trademark of Boehringer Ingelheim, used under license.